Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

General Use-Results Study of Calquence Capsules 100 mg in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

NCT05665374 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05665374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05665374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
General Use-Results Study of Calquence Capsules 100 mg in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 19, 2023
Completion date
August 20, 2025
Enrollment
67 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

previously untreated chronic lymphocytic leukaemia (including small lymphocytic lymphoma)